Toggle Main Menu Toggle Search

Open Access padlockePrints

Chemoenzymatic total synthesis of the antibiotic (−)-13-deoxytetrodecamycin using the Diels-Alderase TedJ

Lookup NU author(s): Monse Manzo Ruiz, Professor Paul RaceORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2025 The Royal Society of Chemistry. The tetrodecamycins are tetracyclic natural products that exhibit potent antimicrobial activity against a multitude of drug-resistant pathogens. These compounds are structurally distinguished by the presence of a tetronate ring and trans-decalin with six contiguous asymmetric centres united by a seven-membered oxygen heterocycle. Herein we describe the first total synthesis of the antibiotic (−)-13-deoxytetrodecamycin. Our strategy is predicated on an enantioselective [4 + 2]-cycloaddition catalysed by the FAD-dependent Diels-Alderase TedJ, forming the trans-decalin with concomitant creation of two rings and four contiguous stereocenters with exquisite selectivity under mild conditions. In complementary studies, in vitro enzyme assays, X-ray crystallography and computational modelling are used to provide molecular insights into the TedJ catalysed reaction. These studies illustrate the power of adopting a chemoenzymatic approach for the enantioselective synthesis of a target compound which would be difficult to achieve using non-biological methods and provide a practical demonstration of the use of Diels-Alder biocatalysts in total synthesis. This approach has potentially widespread value in the global challenge of discovery and development of new antibiotics.


Publication metadata

Author(s): Russell SJ, Back CR, Perry C, Cheung KA, Maschio L, Charlton SN, Lees NR, Manzo-Ruiz M, Hayes MA, van der Kamp MW, Race PR, Willis CL

Publication type: Article

Publication status: Published

Journal: Chemical Science

Year: 2025

Volume: 16

Issue: 36

Pages: 16993-16999

Print publication date: 28/09/2025

Online publication date: 26/08/2025

Acceptance date: 17/08/2025

Date deposited: 30/09/2025

ISSN (print): 2041-6520

ISSN (electronic): 2041-6539

Publisher: Royal Society of Chemistry

URL: https://doi.org/10.1039/d5sc05480j

DOI: 10.1039/d5sc05480j

Data Access Statement: The data supporting this article have been reported as part of the SI. Supplementary information is available and includes experimental procedures, analytical and spectral data, NMR spectra, computational methods, protein expression, purification, crystallisation and X-ray. See DOI: https://doi.org/10.1039/d5sc05480j.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
AstraZeneca, Sweden
BBSRC SWBio DTP3 BB/T008741/1
BBSRC/EPSRC funded BrisSynBio Synthetic Biology Research Centre (BB/L01386X/1)
Conacyt 766585
BBSRC grants BB/T001968/1, BB/M012107/1 (X-ray), and BB/Y000846/1
CoEBio3
EPSRC Centre for Doctoral Training in Synthetic Biology, EP/L016494/1
EPSRC Bristol Chemical Synthesis Centre for Doctoral Training, EP/G036764/1
EPSRC Technology Enhanced Centre for Doctoral Training EP/L015366/1

Share